MBX Biosciences to Participate in November Investor Conferences
MBX Biosciences (Nasdaq: MBX) announced that CEO Kent Hawryluk and CMO Sam Azoulay, M.D., will present at four investor conferences in November 2025: Guggenheim (Nov 10, Boston), Stifel (Nov 12, New York), Jefferies (Nov 19, London) and TD Cowen virtual summit (Nov 24).
Formats include fireside chats and 1x1 meetings; listed times are local to each event. Live webcasts and replays will be available in the events section of the company investor website and archived for about 90 days.
MBX Biosciences (Nasdaq: MBX) ha annunciato che il CEO Kent Hawryluk e il CMO Sam Azoulay, M.D., parteciperanno a quattro conferenze per investitori a novembre 2025: Guggenheim (11 nov, Boston), Stifel (12 nov, New York), Jefferies (19 nov, Londra) e TD Cowen virtual summit (24 nov).
I format includono chiacchierate informali e incontri one-to-one; gli orari indicati sono locali per ogni evento. Le dirette web e le repliche saranno disponibili nella sezione eventi del sito investitore dell'azienda e saranno archiviate per circa 90 giorni.
MBX Biosciences (Nasdaq: MBX) anunció que el CEO Kent Hawryluk y el CMO Sam Azoulay, M.D., presentarán en cuatro conferencias para inversionistas en noviembre de 2025: Guggenheim (11/10, Boston), Stifel (11/12, Nueva York), Jefferies (11/19, Londres) y TD Cowen cumbre virtual (11/24).
Los formatos incluyen charlas junto a la chimenea y reuniones 1x1; los horarios indicados son locales para cada evento. Las transmisiones en vivo y las repeticiones estarán disponibles en la sección eventos del sitio para inversionistas de la empresa y se archivarán por unos 90 días.
MBX Biosciences (나스닥: MBX)는 CEO Kent Hawryluk과 CMO Sam Azoulay, M.D.가 2025년 11월에 네 차례의 투자자 컨퍼런스에서 발표할 것이라고 발표했습니다: Guggenheim(11월 10일, 보스턴), Stifel(11월 12일, 뉴욕), Jefferies(11월 19일, 런던) 및 TD Cowen 가상 정상회담(11월 24일).
포맷은 fireside 챗과 1대1 미팅을 포함합니다; 기재된 시간은 각 이벤트의 현지 시간입니다. 라이브 웹캐스트와 재방송은 회사 투자자 웹사이트의 events 섹션에서 이용 가능하며 약 90일 보관됩니다.
MBX Biosciences (NASDAQ: MBX) a annoncé que le PDG Kent Hawryluk et le CMO Sam Azoulay, M.D., présenteront lors de quatre conférences investisseurs en novembre 2025 : Guggenheim (11 novembre, Boston), Stifel (12 novembre, New York), Jefferies (19 novembre, Londres) et le sommet virtuel TD Cowen (24 novembre).
Les formats incluent des « fireside chats » et des rencontres en tête-à-tête ; les heures indiquées sont locales à chaque événement. Les webcasts en direct et les rediffusions seront disponibles dans la section événements du site investisseurs de l'entreprise et seront archivés pendant environ 90 jours.
MBX Biosciences (Nasdaq: MBX) gab bekannt, dass CEO Kent Hawryluk und CMO Sam Azoulay, M.D., auf vier Investorenkonferenzen im November 2025 präsentieren werden: Guggenheim (10. Nov, Boston), Stifel (12. Nov, New York), Jefferies (19. Nov, London) und TD Cowen Virtueller Gipfel (24. Nov).
Die Formate umfassen Fireside-Chats und 1-zu-1-Meetings; die angegebenen Zeiten gelten jeweils lokal. Live-Webcasts und Wiederholungen sind im Events-Bereich der Unternehmensinvestorenseite verfügbar und etwa 90 Tage archiviert.
MBX Biosciences (ناسداك: MBX) أعلنت أن الرئيس التنفيذي كينت هواريلوك والمدير التنفيذي للتسويق سام أزولاي، دكتور في الطب، سيقدمان في أربع مؤتمرات استثمارية في نوفمبر 2025: Guggenheim (10 نوفمبر، بوسطن)، Stifel (12 نوفمبر، نيويورك)، Jefferies (19 نوفمبر، لندن) وقمة TD Cowen الافتراضية (24 نوفمبر).
تشمل الصيغ حديث الموقد واللقاءات 1×1؛ الأوقات المذكورة محلية لكل حدث. ستكون البثوث الحية ومراقبة الإعادات متاحة في قسم الأحداث من موقع المستثمرين للشركة ومؤرشَفة لمدة نحو 90 يوماً.
MBX Biosciences (纳斯达克：MBX)宣布，CEO Kent Hawryluk 与 CMO Sam Azoulay, M.D.，将在2025年11月的四场投资者会议上发言：Guggenheim（11月10日，波士顿）、Stifel（11月12日，纽约）、Jefferies（11月19日，伦敦）以及 TD Cowen 虚拟峰会（11月24日）。
形式包括炉边谈话和一对一会谈；所列时间以各自活动当地时间为准。现场网络直播和重播将可在公司投资者网站的events栏目查看，并保留大约90天。
- None.
- None.
CARMEL, Ind., Oct. 20, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will present at and participate in the following upcoming investor conferences:
Guggenheim 2nd Annual Healthcare Innovation Conference
Date: Monday, November 10, 2025
Format: Fireside chat and 1x1 meetings
Time: 3:30 p.m. – 3:55 p.m. ET
Location: Boston, MA
Stifel Healthcare Conference
Date: Wednesday, November 12, 2025
Format: Fireside chat and 1x1 meetings
Time: 3:20 p.m. – 3:50 p.m. ET
Location: New York, NY
Jefferies Global Healthcare Conference
Date: Wednesday, November 19, 2025
Format: Fireside chat and 1x1 meetings
Time: 4:00 p.m. – 4:25 p.m. GMT
Location: London, UK
TD Cowen Treatment Advancements in Obesity and Related Disorders Summit
Date: Monday, November 24, 2025
Format: Fireside chat and 1x1 meetings
Time: 10:00 a.m. – 10:25 a.m. ET
Location: Virtual
The live webcasts can be accessed in the events section of the MBX Biosciences website at https://investors.mbxbio.com/news-events/events. Access to the webcast replays will be available approximately two hours after the completion of the events and will be archived on the Company’s website for approximately 90 days.
About MBX Biosciences
MBX Biosciences is a biopharmaceutical company focused on the discovery and development of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism (HP) preparing for Phase 3 development; imapextide (1416) for the treatment of post-bariatric hypoglycemia (PBH) in Phase 2 development; and an obesity portfolio that includes MBX 4291 in Phase 1 development, as well as multiple discovery and pre-clinical obesity candidates. The Company is based in Carmel, Indiana. To learn more, please visit the Company website at https://mbxbio.com/ and follow it on LinkedIn.
Media Contact:
Katie Beach Oltsik
Inizio Evoke Comms
katie.beach@inizioevoke.com
(937) 232-4889
Investor Contact:
Jim DeNike
MBX Biosciences
jdenike@mbxbio.com
FAQ
When will MBX Biosciences (MBX) present at the Guggenheim Healthcare Innovation Conference?
How can investors watch MBX (MBX) presentations from the November 2025 conferences?
Which MBX executives will present at the November 2025 investor conferences?
What is MBX's schedule for the Jefferies Global Healthcare Conference in November 2025?
Will MBX present at an event focused on obesity treatments in November 2025?
Where are the November 2025 MBX investor conference locations and formats?
